Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study.
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis.
Brain reserve and cognitive reserve in multiple sclerosis: What you've got and how you use it.
Dynamic imaging of individual remyelination profiles in multiple sclerosis.
Morphological differentiation of oligodendrocytes requires activation of Fyn tyrosine kinase.
Stimulated PBMC-produced IFN-γ and TNF-α are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study.
Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance.
CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.
Self-reactive CD4(+) T cells activated during viral-induced demyelination do not prevent clinical recovery.
Imaging Neurodegeneration and Repair in Multiple Sclerosis
Race to Erase MS Forum and Expo
IFNγ-stimulated dendritic cell exosomes as a potential therapeutic for remyelination.
Treatment of neuromyelitis optica.
Imaging outcomes for trials of remyelination in multiple sclerosis.
CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.
Role of the Blood-Brain Barrier in Multiple Sclerosis.
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis.
Human herpesvirus 6 and effectiveness of interferon β1b in multiple sclerosis patients.
Amiloride: a molecular probe of sodium transport in tissues and cells.
Tip variant focal segmental glomerulosclerosis associated with interferon-β treatment of multiple sclerosis.
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
Mountain View Pharmaceuticals receives European patent on potential long-acting drug for multiple sclerosis
Environmental risk factors for multiple sclerosis. Part I: the role of infection.
Multiple sclerosis: an immune or neurodegenerative disorder?
Reversal of Paralysis and Reduced Inflammation from Peripheral Administration of β-Amyloid in TH1 and TH17 Versions of Experimental Autoimmune Encephalomyelitis.

Pages